Rapidly developing disruptive treatments for today’s most challenging diseases
Eikonoklastes is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet medical need, starting with neurodegenerative diseases and cancers.
We’re relentlessly striving to rapidly advance a new generation of medicines where value is most efficiently generated. Most importantly, we will significantly improve the lives of patients and families suffering from the most devastating diseases.
We are iconoclasts passionate about building a new kind of biotech company. One that breaks the mold by developing a pipeline of novel compounds initially tailored toward areas with the strongest benefit/risk (e.g., rare disease and oncology) and then collaborating with strategic partners to further explore the immense potential in larger indications.
Eikonoklastes is pushing the frontiers in multiple areas of severe unmet clinical need. Our dynamic discovery and development approach allows us to focus on accelerated approvals and outsized returns for multiple compounds. Our first two assets are on track for Phase 1/2a studies in 2023, with several additional therapies and potential partnerships on the horizon.
SynCav1 is a first-in-class, non-monogenic gene therapy platform to treat a wide range of neurodegenerative diseases with precise, targeted overexpression of Caveolin-1.
Engineered for safety
Intraspinal delivery minimizes dose requirements and significantly reduces systemic exposure and thus the possibility of liver toxicity and immunogenicity.
Demonstrated improvement in quality of life and survival in Amyotrophic Lateral Sclerosis (ALS) models and improved memory in Alzheimer’s disease models.
LEAD INDICATION: Our lead indication is ALS, which is eligible for Orphan Drug and Breakthrough designation. ALS is a rare neurological disease with significant socioeconomic impact whose patients are desperate for novel safe and effective therapies.
Delivering additional copies of a specific gene to induce neuroprotection
SynCav1 is a gene therapy that has been engineered by Dr. Brian Head to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function. Research has shown that increasing Caveolin-1 leads to a neuroprotective effect so that nerve cells can compensate for the neurodegenerative process caused by the underlying disease, allowing the cells to stay healthier and improving their functional ability. This increase leads to healthier nerve cells and better communication between them. By maintaining nerve cell health, SynCav1 could be an option for a wide range of neurodegenerative diseases.
L-ICON3 is a novel tissue factor (TF)-targeting immunoconjugate agent, with enhanced delivery and efficacy against multiple solid tumors and other pathologic conditions.
Proprietary, state of the art molecule discovered and engineered by scientific founder, Dr Zhiwei Hu—one of the early pioneers of TF-targeting therapies.
Optimized for efficacy
Designed for greater potency and selectivity, improved safety, and immune activation.
LEAD INDICATION: Our lead indication is Triple Negative Breast Cancer (TNBC), which accounts for 15% of all breast cancers. TNBC is an aggressive cancer and in most cases considered incurable with an 18-month life expectancy from initial diagnosis.
Launching a 3-pronged immune attack on the tumor microenvironment
L-ICON3 is a conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem cells, to trigger complement activation (CDC) and antibody dependent cellular cytotoxicity (ADCC) killing of the pathologic cells.
|Traumatic Brain Injury|
- Director, New Drug Development, P&G Pharmaceuticals
- Co-founder, Myonexus Therapeutics
- COO, N8 Medical, Kinnear Pharmaceuticals and Myonexus Therapeutics
Dr. Bruce Halpryn co-founded Eikonoklastes in 2019 and has served as Chairman of our Board of Directors, President, and Chief Executive Officer since 2019. Dr. Halpryn has more than 30 years of experience in the industry with involvement in the formation and the leadership of four early stage biotechnology companies as well as global biopharmaceutical companies. Prior to Eikonoklastes, Bruce co-founded Myonexus Therapeutics (acquired by Sarepta in 2018), and served as Chief Operating Officer and as a member of its Board of Directors. Dr. Halpryn has extensive experience in designing and leading biologics and small molecule drug development programs and companies across a broad range of therapeutic areas.
Earlier in his career, Dr. Halpryn led the Congestive Heart Failure Research Lab at Norwich Eaton Pharmaceuticals before its acquisition by the Proctor & Gamble Company and subsequently renamed P&G Pharmaceuticals. He then led drug discovery, development, and commercialization efforts for P&G Pharmaceuticals, playing a key role in the strategic design and program leadership of numerous successful approvals.
Bruce is a cardiovascular physiologist by education and conducted his post-doctoral fellowship as a National Research Council Fellow at NASA/Ames Research Center. He holds a Ph.D. in Biology/Physiology from SUNY Binghamton.
- Venture capitalist at CincyTech, leading multiple successful life science investments
- Chairman, Invirsa
Dr. Samuel Lee co-founded Eikonoklastes in 2019 and has served as a member of our Board of Directors and Chief Business Officer since 2019. Dr. Lee brings a multidisciplinary convergence of experiences in the life sciences, physical sciences, and computer sciences to successfully develop breakthroughs in healthcare. Prior to Eikonoklastes, Sam was a Director at CincyTech, a venture capital firm, where he led investments and actively supported operations in biotech and medical device portfolio companies such as Myonexus (acquired by Sarepta) and Blue Water Vaccines (NASDAQ: BWV).
Dr. Lee completed his medical training at the University of Cincinnati, formal business and public health education at the Stanford Graduate School of Business and Johns Hopkins, and post-graduate research fellowship at Northwestern University and Cincinnati Children’s Hospital Medical Center. Dr. Lee also serves as Chairman of the Board of Directors at Invirsa and is an Executive-in-Residence at CincyTech.
- Extensive experience in early and late phase drug development in multiple therapeutic areas
- R&D leadership experience with corporate partnerships and international joint ventures
Dr. Mark Dato has more than 25 years of experience in biopharmaceutical drug development, basic science research, and clinical practice. Dr. Dato has held global R&D leadership roles on numerous drugs from preclinical into clinical development, resulting in multiple approvals by the FDA, EMEA, and sFDA. Mark has also played key roles in designing programs to bring numerous OTC medications to markets in EU, Latin America, and Asia. Prior to Eikonoklastes, Dr. Dato was the Director of Global Technology for P&G/Teva Pharmaceuticals Joint Venture Healthcare in Geneva, Switzerland after holding various positions of increasing responsibility in product safety, pharmacovigilance, product development, regulatory, and corporate M&A for the Proctor & Gamble Company.
Dr. Dato holds an M.D. and Ph.D. (Immunology) from Chicago Medical School. He completed his residency training in Pediatrics and fellowship in Pediatric Pulmonology at Cincinnati Children’s Hospital Medical Center, and he served on the faculty at Cincinnati Children’s Hospital.
- World leading expert in Caveolin biology
- Inventor of Eikonoklastes gene therapy platform
- Pioneer in Tissue Factor biology
- Inventor of Eikonoklastes immunotherapy platform
- Leading expert in antibody and gene therapy manufacturing for several successful private and publicly traded biotech companies
Dr. Vishal Agrawal joined Eikonoklastes in 2022 as our Vice President of CMC and Process Development. Prior to joining Eikonoklastes, Vishal worked at a number of successful private and publicly-traded biotech companies with increasing responsibility in both antibody and gene therapy manufacturing. Dr. Agrawal completed his Bachelors and Masters in Biochemical Engineering at The Indian Institutes of Technology Delhi and his PhD in Cell Biology at Max-Delbruck Centre.
Elk Capital Markets